JP2022519068A5 - - Google Patents
Info
- Publication number
- JP2022519068A5 JP2022519068A5 JP2021544532A JP2021544532A JP2022519068A5 JP 2022519068 A5 JP2022519068 A5 JP 2022519068A5 JP 2021544532 A JP2021544532 A JP 2021544532A JP 2021544532 A JP2021544532 A JP 2021544532A JP 2022519068 A5 JP2022519068 A5 JP 2022519068A5
- Authority
- JP
- Japan
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024139375A JP7760010B2 (ja) | 2019-02-01 | 2024-08-21 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
| JP2025171516A JP2026016453A (ja) | 2019-02-01 | 2025-10-10 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799851P | 2019-02-01 | 2019-02-01 | |
| US62/799,851 | 2019-02-01 | ||
| PCT/US2020/015841 WO2020160242A1 (en) | 2019-02-01 | 2020-01-30 | Anti-il2 receptor gamma antigen-binding proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139375A Division JP7760010B2 (ja) | 2019-02-01 | 2024-08-21 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022519068A JP2022519068A (ja) | 2022-03-18 |
| JP2022519068A5 true JP2022519068A5 (https=) | 2023-02-06 |
| JPWO2020160242A5 JPWO2020160242A5 (https=) | 2023-02-06 |
| JP7544724B2 JP7544724B2 (ja) | 2024-09-03 |
Family
ID=69740681
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544532A Active JP7544724B2 (ja) | 2019-02-01 | 2020-01-30 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
| JP2024139375A Active JP7760010B2 (ja) | 2019-02-01 | 2024-08-21 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
| JP2025171516A Pending JP2026016453A (ja) | 2019-02-01 | 2025-10-10 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139375A Active JP7760010B2 (ja) | 2019-02-01 | 2024-08-21 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
| JP2025171516A Pending JP2026016453A (ja) | 2019-02-01 | 2025-10-10 | 抗ｉｌ２受容体ガンマ抗原結合タンパク質 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11629195B2 (https=) |
| EP (2) | EP4717318A2 (https=) |
| JP (3) | JP7544724B2 (https=) |
| KR (1) | KR20210123350A (https=) |
| CN (3) | CN120157766A (https=) |
| AU (2) | AU2020214812B2 (https=) |
| BR (1) | BR112021014074A2 (https=) |
| CA (1) | CA3126117A1 (https=) |
| CL (1) | CL2021002008A1 (https=) |
| CO (1) | CO2021009693A2 (https=) |
| DK (1) | DK3917962T3 (https=) |
| EA (1) | EA202192090A1 (https=) |
| IL (1) | IL284579A (https=) |
| MX (1) | MX2021008958A (https=) |
| MY (1) | MY203138A (https=) |
| PH (1) | PH12021500031A1 (https=) |
| PT (1) | PT3917962T (https=) |
| SG (1) | SG11202107272SA (https=) |
| WO (1) | WO2020160242A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021008958A (es) * | 2019-02-01 | 2021-11-04 | Regeneron Pharma | Proteínas de unión a antígeno del receptor gamma anti-il2. |
| EP4139341A1 (en) | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| CN118251416A (zh) * | 2021-11-02 | 2024-06-25 | 上海岸迈生物科技有限公司 | 抗cd122抗体、抗cd132抗体及相关的双特异性结合蛋白 |
| CN114990206B (zh) * | 2022-06-02 | 2023-04-07 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用 |
| JP2025523802A (ja) | 2022-07-13 | 2025-07-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 分析物を検出するための弱酸性免疫アッセイ |
| CN120265314A (zh) | 2022-09-28 | 2025-07-04 | 瑞泽恩制药公司 | 抗体抗性修饰受体以增强基于细胞的疗法 |
| CN118480118B (zh) * | 2022-10-21 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| WO2024138175A1 (en) * | 2022-12-22 | 2024-06-27 | Forte Subsidiary, Inc. | Methods of treating acute and chronic graft versus host diseases |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026033139A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3255699B2 (ja) | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトＩＬ−２レセプターγ鎖分子 |
| US6576236B1 (en) | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
| WO1997017360A2 (en) | 1995-11-09 | 1997-05-15 | Dana-Farber Cancer Institute | Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain |
| EP0918858A1 (en) | 1996-05-10 | 1999-06-02 | Biogen, Inc. | Common gamma chain blocking agents |
| US6861227B2 (en) | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| WO2001077288A2 (en) | 2000-04-06 | 2001-10-18 | Genetics Institute, Llc. | Polynucleotides encoding novel secreted proteins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| WO2011127324A2 (en) * | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
| AU2012205663B2 (en) | 2011-01-10 | 2017-02-02 | Emory University | Antibodies directed against influenza |
| EA035987B1 (ru) | 2012-09-12 | 2020-09-09 | Джензим Корпорейшн | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| KR102876923B1 (ko) * | 2015-10-23 | 2025-10-28 | 화이자 인코포레이티드 | 항-il-2 항체 및 조성물 및 이의 용도 |
| WO2018156649A1 (en) | 2017-02-22 | 2018-08-30 | Flagship Pioneering, Inc. | Compositions of t cell modulator (tcm) molecules and uses thereof |
| MX2021008958A (es) * | 2019-02-01 | 2021-11-04 | Regeneron Pharma | Proteínas de unión a antígeno del receptor gamma anti-il2. |
-
2020
- 2020-01-30 MX MX2021008958A patent/MX2021008958A/es unknown
- 2020-01-30 US US16/776,928 patent/US11629195B2/en active Active
- 2020-01-30 EP EP26156344.9A patent/EP4717318A2/en active Pending
- 2020-01-30 BR BR112021014074A patent/BR112021014074A2/pt unknown
- 2020-01-30 WO PCT/US2020/015841 patent/WO2020160242A1/en not_active Ceased
- 2020-01-30 EP EP20708887.3A patent/EP3917962B1/en active Active
- 2020-01-30 JP JP2021544532A patent/JP7544724B2/ja active Active
- 2020-01-30 CN CN202510314681.7A patent/CN120157766A/zh active Pending
- 2020-01-30 MY MYPI2021003809A patent/MY203138A/en unknown
- 2020-01-30 DK DK20708887.3T patent/DK3917962T3/da active
- 2020-01-30 KR KR1020217027926A patent/KR20210123350A/ko not_active Ceased
- 2020-01-30 CN CN202510314674.7A patent/CN120157765A/zh active Pending
- 2020-01-30 EA EA202192090A patent/EA202192090A1/ru unknown
- 2020-01-30 CN CN202080012091.4A patent/CN113474370B/zh active Active
- 2020-01-30 AU AU2020214812A patent/AU2020214812B2/en active Active
- 2020-01-30 PT PT207088873T patent/PT3917962T/pt unknown
- 2020-01-30 CA CA3126117A patent/CA3126117A1/en active Pending
- 2020-01-30 PH PH1/2021/500031A patent/PH12021500031A1/en unknown
- 2020-01-30 SG SG11202107272SA patent/SG11202107272SA/en unknown
-
2021
- 2021-07-04 IL IL284579A patent/IL284579A/en unknown
- 2021-07-23 CO CONC2021/0009693A patent/CO2021009693A2/es unknown
- 2021-07-29 CL CL2021002008A patent/CL2021002008A1/es unknown
-
2023
- 2023-02-15 US US18/169,345 patent/US20230279131A1/en active Pending
-
2024
- 2024-08-21 JP JP2024139375A patent/JP7760010B2/ja active Active
-
2025
- 2025-10-10 JP JP2025171516A patent/JP2026016453A/ja active Pending
- 2025-10-16 AU AU2025252566A patent/AU2025252566A1/en active Pending